Shares of Compugen Ltd. (NASDAQ:CGEN) traded up 2.9% during mid-day trading on Monday . The company traded as high as $3.80 and last traded at $3.90, 2,000 shares traded hands during mid-day trading. A decline of 99% from the average session volume of 376,143 shares. The stock had previously closed at $3.79.
Separately, Zacks Investment Research raised Compugen from a “hold” rating to a “strong-buy” rating and set a $3.75 price objective for the company in a report on Thursday, August 8th.
The firm has a market capitalization of $194.39 million, a P/E ratio of -9.49 and a beta of 2.65. The business has a fifty day moving average of $3.49 and a 200-day moving average of $3.54. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.38 and a current ratio of 5.38.
A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada lifted its position in Compugen by 115.4% during the 2nd quarter. Royal Bank of Canada now owns 57,500 shares of the biotechnology company’s stock worth $221,000 after buying an additional 30,800 shares in the last quarter. Jane Street Group LLC lifted its position in Compugen by 20.5% during the 2nd quarter. Jane Street Group LLC now owns 65,721 shares of the biotechnology company’s stock worth $252,000 after buying an additional 11,192 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new stake in Compugen during the 2nd quarter worth about $45,000. Morgan Stanley lifted its position in Compugen by 2.1% during the 2nd quarter. Morgan Stanley now owns 1,035,175 shares of the biotechnology company’s stock worth $3,975,000 after buying an additional 21,368 shares in the last quarter. Finally, ETF Managers Group LLC bought a new stake in Compugen during the 2nd quarter worth about $424,000. 29.86% of the stock is owned by institutional investors and hedge funds.
Compugen Company Profile (NASDAQ:CGEN)
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
See Also: Call Option Volume
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.